Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial
In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.
Authors
- Susanne Stowasser (ORCID: https://orcid.org/0009-0008-6013-0225)
- Luca Richeldi
- Arata Azuma
- Marlies S. Wijsenbeek
- Justin M. Oldham
- Anna-Maria Hoffmann-Vold
- Ivana Ritter
- Hui Gu
- Michael Kreuter
- Shervin Assassi
- Claudia Valenzuela
- on behalf of the FIBRONEER-ILD trial investigators
- Toby M. Maher
- Vincent Cottin
- Fernando J. Martinez
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Università Cattolica del Sacro Cuore (IT)
- University of Southern California (US)
- Oslo University Hospital (NO)
- UMass Memorial Health Care (US)
- Boehringer Ingelheim (Germany) (DE)
- Johannes Gutenberg University Mainz (DE)
- University of Zurich (CH)
- University of Michigan (US)
- Erasmus MC (NL)
- University Hospital of Zurich (CH)
- Hospices Civils de Lyon (FR)
- Hospital Universitario de La Princesa (ES)
- Hôpital Louis Pradel (FR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- The University of Texas Health Science Center (US)
- Boehringer Ingelheim (United States) (US)
- UMass Memorial Medical Center (US)
- Imperial College London (GB)
- Universidad Autónoma de Madrid (ES)
- Nippon Medical School (JP)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1183/13993003.01899-2025
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00